drug

aprocitentan

Marketedupdated 2mo ago

by Idorsia Pharmaceuticals US Inc

Approved

community read0 votes

indications

investigational

Hypertension

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 22, 2029

~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Jul 26, 2038method-of-use (U-3878)US 11680058
Mar 2, 2038method-of-use (U-3877)US 11787782
Feb 26, 2038compositionUS 10919881
Feb 26, 2038formulationUS 12297189
Nov 6, 2037method-of-use (U-3879)US 11174247
Sep 21, 2029compositionUS 83242323.2y

FDA exclusivities (1)

Mar 22, 2029NCENew Chemical Entity (5y)2.7y

Data sources

ClinicalTrials.gov

last refreshed 11m ago

Found something off?

Trials studying aprocitentan

phase1A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptivescompletedn=19